Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina

https://doi.org/10.20996/1819-6446-2020-06-12

Full Text:

Abstract

Background. Despite the progress in the diagnostics of microvascular angina (МА) there is no effective pathogenetic therapy.

Aim. To study the effect of trimetazidine and sulodexide as a part of drug therapy on clinical manifestations, exercise tolerance, quality of life, myocardial perfusion and endothelial function in patients with MA.

Material and methods. Patients with MA (n=90) were included into the study and randomized into 3 groups. Patients of the first group (control; n=30) received standard antianginal therapy. The second group (treatment group; n=30) received standard therapy and sulodexide (1 ampoule of 600 IU intramuscularly for 10 days, then 1 capsule of 250 IU, 2 times a day). Patients of the third group (treatment group; n=30) received standard therapy and trimetazidine with modified release 35 mg 2 times a day. Evaluation of angina symptoms and quality of life by the Seattle Questionnaire, stress (treadmill) test, positron emission tomography (baseline, adenosine test, cold-pressor test), peripheral arterial tonometry were performed at baseline and 3 months after starting treatment.

Results. After 3 months of treatment a significant improvement in symptoms, quality of life and results of stress-test were observed only among patients of treatment groups, most pronounced in the 3rd group. Patients of this group showed an increase in myocardial blood flow >25% according to positron emission tomography (from 86.2±29.7 to 129.5±41.0 ml/100g/min, p<0.05 for anterior interventricular artery; from 93.3±30.5 to 131.7±32.7 ml/100g/min, p<0.05 for circumflex artery; from 91.3±30.4 to 135.9±41.1 ml/100g/min, p<0.05 for right coronary artery) and a significant increase in coronary reserve, as well as an improvement in endothelial function: an increase in coronary reserve of endothelium-dependent vasodilation, an increase in the reactive hyperemia index according to peripheral arterial tonometry (from 1.44±0.14 to 1.73±0.18, p<0.001).

Conclusion. Improvement of the clinical picture, quality of life, myocardial perfusion, and endothelial function was observed among microvascular angina patients who were treated with standard antianginal therapy and trimetazidine.

About the Authors

S. A. Boldueva
North-Western State Medical University named after I.I. Mechnikov
Russian Federation

Svetlana A. Boldueva - MD, PhD, Professor, Head of Chair of Faculty Therapy, North-Western State Medical University named after I.I. Mechnikov.

Kirochnaya ul. 41, St-Petersburg, 191015.



I. A. Leonova
North-Western State Medical University named after I.I. Mechnikov
Russian Federation

Irina A. Leonova - MD, PhD, Associate Professor, Chair of Faculty Therapy, North-Western State Medical University named after I.I. Mechnikov.

Kirochnaya ul. 41, St-Petersburg, 191015.



O. V. Zakharova
North-Western State Medical University named after I.I. Mechnikov
Russian Federation

Olga V. Zakharova - MD, PhD, Assiatant, Chair of Faculty Therapy, North-Western State Medical University named after I.I. Mechnikov.

Kirochnayaul. 41, St-Petersburg, 191015.



References

1. Makarovic Z., Makarovic S., Bilic-Cucic I., et al. Nonobstructive coronary artery disease - clinical relevance, diagnosis, management and proposal of new pathophysiological classification. Acta Clin Croat. 2018;57(3):528-41. DOI:10.20471/acc.2018.57.03.17.

2. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. DOI:10.1093/eurheartj/eht296.

3. Lanza G.A., Crea F., Kaski J.C. Clinical outcomes in patients with primary stable microvascular angina: is the Jury still out? Eur Heart J Qual Care Clin Outcomes. 2019;5(4):283-91. DOI:10.1093/ ehjqcco/qcz029.

4. Lanza G.A., Parrinello R., Figliozzi S. Management of microvascular angina pectoris. Am J Cadiovasc Drugs. 2014;14(1):31-40. DOI:10.1007/s40256-013-0052-1.

5. Marzilli M., Vinereanu D., Lopaschuk G., et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019;293:39-44. DOI:10.1016/j.ijcard.2019.05.063.

6. AltintigbreveА., Yilmaz Н., Nalbantgil I.I., Onder R. The Effect of Trimetazidinein the Treatment of Microvascular Angina. Int J Angiol. 1999;8:40-3. DOI:10.1007/bf01616842.

7. Rogacka D., Guzik P., Wykretowicz А., et. al. Effects of trimetazidine on clinical symptoms and tolerance of exercise of patients with syndrome X: a preliminary study. Coron Artery Dis. 2000;11:171-7. DOI:10.1097/00019501-200003000-00012.

8. Leonardo F, Fragasso G., Rossetti E., et. al. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance Cardiologia (Rome, Italy). 1999;44:1065-9.

9. Weiss R., Niecestro R., Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67(18):2681-96. DOI:10.2165/00003495-200767180-00004.

10. Chan P.S., Jones P.G., Arnold S.A., Spertus J.A. Development and validation of a short version of the Seattle angina questionnaire Circ Cardiovasc Qual Outcomes. 2014;7(5):640-7. DOI:10.1161/CIR-COUTCOMES.114.000967.

11. Ryzhkova D.V., Kolesnichenko M.G., Baldueva S.A., et al. Study of the state of coronary hemodynamics by positron emission tomography in patients with cardiac X syndrome. Sibirsky Medical Journal. 2012;27(2):48-54 (In Russ.)

12. Lipunova A. S., Boldueva S.A., et al. The role of endothelial dysfunction in the genesis of cardiac syndrome X. Preventive and Clinical Medicine. 2013;1(46):38-42 (In Russ.)

13. Boldueva S.A., Leonova I.A. Primary microvascular angina (cardiac syndrome X): clinical manifestations, prognosis, diagnosis, treatment. Serdtse. 2016;15(5):307-19 (In Russ.). DOI:10.18087/rhj.2016.5.2199.

14. Boldueva S.A., Leonova I.A. Primary microvascular angina pectoris (cardiac syndrome X). Controversial and unresolved issues: terminology, definitions, pathogenetic mechanisms. Serdtse. 2016;15(4):223-34 (In Russ.). DOI:10.18087/rhj.2016.4.2196.

15. Park K.H., Park W.J., Kim M.K., et. al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery Am. J. Cardiol. 2010;105:1723-27. DOI:10.1016/j.amjcard.2010.01.351.

16. Belardinelli R., Solenghi M., Volpe L., et. al. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J. 2007;28(9):1102-8. DOI:10.1093/eurheartj/ehm071.

17. Fadini G.P., Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes, Obesity & Metabolism. 2010;12(7):570-83. DOI:10.1111/j.1463-1326.2010.01210.x.

18. Ruixing Y., Wenwu L., Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Translational Research. 2007;149(3):152-60. DOI:10.1016/j.trsl.2006.11.004.


For citation:


Boldueva S.A., Leonova I.A., Zakharova O.V. Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina. Rational Pharmacotherapy in Cardiology. 2020;16(3):363-369. (In Russ.) https://doi.org/10.20996/1819-6446-2020-06-12

Views: 155


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)